GEN Exclusives

More »

GEN News Highlights

More »
Jan 10, 2007

Erbitux Phase III Metastatic Colorectal Cancer Study Meets Primary Endpoint

  • ImClone Systems and Bristol-Myers Squibb reported that a Phase III study of Erbitux in metastatic colorectal cancer (mCRC) showed positive results. Erbitux (cetuximab) plus Folfiri (an irinotecan-based chemotherapy) increased median duration of progression-free survival over Folfiri alone in patients with previously untreated mCRC.

    "These results provide important new information for patients with metastatic colorectal cancer and are part of a comprehensive clinical development program designed to fully understand the potential uses of Erbitux for cancer patients," says Martin Birkhofer, M.D., vp, oncology global medical affairs, Bristol-Myers Squibb.

    The study, in which more than 1,000 patients participated, was conducted by Merck KGaA, ImClone’s Erbitux partner outside of North America. The company hopes to present the results at the ASCO Annual Meeting in June.

    Erbitux’ current indications are related to squamous cell carcinoma of the head and neck and EGFR-expressing metastatic colorectal carcinoma.

     



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?